On Thursday, Shares of Quantum Corporation (NYSE:QTM), dropped -5.19% to $2.01.
Quantum Corporation, reinforced its innovation leadership at the 2015 NAB Show, earning four prestigious awards for its workflow storage and administration solutions. Broadcast Beat recognized the company’s Q-Cloud™ Archive storage service for creativity, and TV Technology magazine named the public cloud service as a Best of Show Award recipient. In addition, Quantum’s StorNext Pro™ Solutions won a StudioDaily Prime Award, and IABM honored the company itself with a Game Changer Award.
Q-Cloud Archive leverages Quantum’s StorNext 5 software to provide automated, policy-based movement of content to a virtually limitless pool of cloud-based storage while delivering fast, seamless access to that content when needed. Because it is fully integrated within a StorNext®-managed environment, Q-Cloud Archive enables users to realize the full benefits of the cloud without having to make changes to their existing applications or processes.
One of hundreds of nominated products in the Broadcast Beat Awards, Q-Cloud Archive earned top honors for creativity in content administration. Judging criteria comprised of the originality of the product, its inventive qualities and ways in which it improves on existing technology.
In giving a Best of Show Award to Q-Cloud Archive, TV Technology judges applauded it for “offering a path to taming the cloud conundrum by integrating it as one component of a hybrid, application-driven infrastructure.”
Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific.
Shares of Arrow Electronics, Inc. (NYSE:ARW), declined -5.16% to $59.71, during its last trading session.
Arrow Electronics, stated first-quarter 2015 net income of $106.1 million, or $1.09 per share on a diluted basis, contrast with net income of $107.1 million, or $1.06 per share on a diluted basis, in the first quarter of 2014. Not taking into account certain items1 in the first quarters of 2015 and 2014, net income would have been $127.8 million, or $1.32 per share on a diluted basis, in the first quarter of 2015, contrast with net income of $124.0 million, or $1.22 per share on a diluted basis, in the first quarter of 2014. First-quarter sales, adjusted for the impact of acquisitions and changes in foreign currencies, raised 3 percent year over year. First-quarter sales of $5 billion, as stated, reduced 2 percent from sales of $5.08 billion in the preceding year. In the first quarter of 2015, changes in foreign currencies had a negative impact of $322 million on sales and a negative impact of $.10 or 9 percent on earnings per share on a diluted basis contrast to the first quarter of 2014.
Global components first-quarter sales, as adjusted, grew 2 percent year over year. First-quarter sales of $3.35 billion, as stated, reduced 2 percent year over year. Global components had one fewer shipping day in the first quarter of 2015 contrast to the first quarter of 2014 and this negatively influenced the rate of sales growth by about 1.5 percentage points. Americas components sales were flat year over year. Europe components sales grew 10 percent year over year on an as-adjusted basis. Sales in the region, as stated, declined 7 percent year over year. Components sales in the Asia-Pacific were flat year over year. Core components sales in Asia-Pacific grew 6 percent year over year.
Global enterprise computing solutions first-quarter sales of $1.66 billion grew 7 percent year over year, as adjusted. Sales, as stated, were flat year over year. Americas sales grew 8 percent year over year. Europe sales grew 8 percent on an as-adjusted basis. Sales in the region, as stated, declined 13 percent year over year. Both Americas and Europe practiced growth across the entirety of the solutions portfolio.
Arrow Electronics, Inc. provides products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions worldwide. The company operates in two segments, Global Components and Global Enterprise Computing Solutions.
At the end of Thursday’s trade, Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), dwindled -5.16% to $10.66, hitting its lowest level.
Keryx Biopharmaceuticals, declared the completion of the formerly declared transition of the CEO role from Ron Bentsur to Greg Madison.
As per Mr. Bentsur’s employment agreement, Mr. Bentsur will also be stepping down from the Company’s Board of Directors, which will be reduced to seven members.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia.
Finally, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), ended its last trade with -5.15% loss, and closed at $3.50.
Synergy Pharmaceuticals, declared its Chief Scientific Officer, Kunwar Shailubhai, PhD, MBA, will give a keynote presentation at the 17th Annual TIDES Summit being held May 3-6, 2015 in San Diego, CA.
The session titled, “Plecanatide and SP-333, Analogues of Uroguanylin, as Innovative Oral Drugs for Treatment of Gastrointestinal Disorders and Diseases”, will be on Monday, May 4th at 11:20am (PDT) at the Town and Country Resort.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
